Adicet Bio Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Adicet Bio's estimated annual revenue is currently $14.1M per year.
- Adicet Bio's estimated revenue per employee is $201,000
- Adicet Bio's total funding is $76.4M.
- Adicet Bio has 70 Employees.
- Adicet Bio grew their employee count by 11% last year.
- Adicet Bio currently has 7 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
What Is Adicet Bio?
Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. Adicet is developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors (CARs) or T Cell Receptors (TCRs). Adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating TCR-like MAbs (TCRLs) directed to these cancer-specific peptide targets presented by MHC Class I complexes. These TCRLs can be used to arm T cells, as T cell engagers or as Antibody Drug Conjugates (ADC). In August 2016, Adicet entered a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics using Adicet's gamma delta T cell allogeneic platform technology. Adicet Bio raised $51M in series A financing led by OrbiMed Partners, OrbiMed Israel, Novartis Venture Fund and Pontifax.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
Adicet Bio News
MENLO PARK, Calif., April 30, 2019 /PRNewswire/ -- Adicet Bio, Inc., a biopharmaceutical company focused on the development of ...
Anil Singhal has been appointed president and CEO of Adicet Bio. He succeeds Donald Santel, who had been interim CEO since founder and ...
Some notable new automated thaw product customers included Adicet Bio, Beam Therapeutics, Bluebird Bio, BlueRock Therapeutics, Editas ...
Adicet Bio Executive Hires
|2017-01-06||Anne Altmeyer||Chief Business Officer||Article|
|2017-06-29||Jesse McGreivy||Chief Medical Officer||Article|
|2017-07-03||Jesse McGreivy||Chief Medical Officer||Article|
|2018-03-07||Donald Santel||interim CEO||Article|
|2018-06-28||Stewart Abbot||Chief Scientific Officer||Article|